Damora Therapeutics, Inc. Common Stock (DMRA) Expected to Announce Earnings on Monday

Key Points

• Damora Therapeutics is expected to report its Q4 2025 results before market open on Monday, March 30, with analysts forecasting earnings of ($0.14) per share and an earnings call noted for Thursday, March 19, 2026 at 7:00 AM ET.
• Shares opened at $18.14 (down about 5.5%), trading between a 12‑month low of $2.01 and high of $38.33, with a market cap of $1.09 billion and a negative P/E of -1.50.
• Analyst sentiment is mixed: MarketBeat reports an average rating of Moderate Buy and a consensus price target of $43.67, while individual ratings range from Strong Buy to Sell.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) is expected to post its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Damora Therapeutics, Inc. Common Stock to post earnings of ($0.14) per share for the quarter. Investors may review the information on the company's upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 19, 2026 at 7:00 AM ET.

Damora Therapeutics, Inc. Common Stock Trading Down 5.5%

Shares of NASDAQ DMRA opened at $18.14 on Monday. Damora Therapeutics, Inc. Common Stock has a 12-month low of $2.01 and a 12-month high of $38.33. The company has a market cap of $1.09 billion, a price-to-earnings ratio of -1.50 and a beta of 1.42. The stock's 50 day simple moving average is $26.93 and its 200 day simple moving average is $19.12.

Analyst Upgrades and Downgrades

DMRA has been the topic of several analyst reports. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, December 29th. Guggenheim restated a "buy" rating and set a $40.00 price target (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, February 17th. Leerink Partners started coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Wednesday, January 7th. They issued an "outperform" rating and a $46.00 price objective on the stock. Lifesci Capital upgraded shares of Damora Therapeutics, Inc. Common Stock to a "strong-buy" rating in a research report on Monday, February 2nd. Finally, Zacks Research upgraded shares of Damora Therapeutics, Inc. Common Stock to a "hold" rating in a research report on Friday, January 9th. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $43.67.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

Several hedge funds have recently added to or reduced their stakes in DMRA. Janus Henderson Group PLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter worth $40,000. Virtu Financial LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the third quarter valued at about $49,000. Two Sigma Investments LP bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the third quarter valued at about $76,000. Connective Capital Management LLC acquired a new stake in Damora Therapeutics, Inc. Common Stock in the third quarter worth about $100,000. Finally, Geode Capital Management LLC bought a new position in Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at about $266,000. Institutional investors own 14.20% of the company's stock.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company's research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.